In the past decade, substantial advances have been made in understanding the biology of
tumour-associated macrophages (TAMs), and their clinical relevance is emerging. A …

Antibody-drug conjugates (ADCs) have emerged as a revolutionary therapeutic class,
combining the precise targeting ability of monoclonal antibodies with the potent cytotoxic …

Background The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide
and dexamethasone has been shown to be effective in patients with relapsed or refractory …

Prolonging overall survival (OS) remains an unmet need in relapsed or refractory multiple
myeloma (RRMM). In ELOQUENT-2 (NCT01239797), elotuzumab plus lenalidomide …

PURPOSE In the phase II ELOQUENT-3 trial (ClinicalTrials. gov identifier: NCT02654132),
elotuzumab combined with pomalidomide/dexamethasone (EPd) significantly improved …

Tumor-associated macrophages (TAMs) exist in nearly all tumors, and form a major part of
the tumor microenvironment. TAMs are divided into two groups: tumor-suppressing M1 type …

Background Elotuzumab plus lenalidomide and dexamethasone has shown improved
progression-free and overall survival versus lenalidomide and dexamethasone in patients …

Multiple myeloma (MM) is a bone marrow plasma cell neoplasm and is the second most-
common hematologic malignancy. Despite advances in therapy, MM remains largely …

Macrophages regulate protective immune responses to infectious microbes, but aberrant
macrophage activation frequently drives pathological inflammation. To identify regulators of …

Unconjugated monoclonal antibodies (mAbs) have revolutionized the treatment of many
types of cancer. Some of these mAbs promote the clearance of malignant cells via direct …